Trials / Completed
CompletedNCT07537283
Coenzyme Q10 as Adjunctive Therapy in Drug-Resistant Epilepsy
A Randomized, Double-Blind, Placebo-Controlled Trial of Coenzyme Q10 as Adjunctive Therapy in Patients With Drug-Resistant Epilepsy
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- National Cheng-Kung University Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the efficacy and safety of coenzyme Q10 supplementation as adjunctive therapy in patients with drug-resistant epilepsy.
Detailed description
This randomized, double-blind, placebo-controlled trial investigates coenzyme Q10 supplementation as adjunctive therapy in patients with drug-resistant epilepsy. Eligible participants will be randomly assigned to receive either coenzyme Q10 or matching placebo in addition to their stable baseline anti-seizure medications. Coenzyme Q10 will be administered orally at a dose of 200 mg per day for 12 weeks. Participants will be followed prospectively with scheduled clinical assessments throughout the study period to evaluate treatment response and safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | coenzyme Q10 | Coenzyme Q10 administered orally as an adjunct to baseline anti-seizure medications for 12 weeks. |
| DIETARY_SUPPLEMENT | Placebo | Matching placebo capsules administered orally once daily for 12 weeks. |
Timeline
- Start date
- 2023-02-07
- Primary completion
- 2023-09-28
- Completion
- 2023-11-28
- First posted
- 2026-04-17
- Last updated
- 2026-04-17
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT07537283. Inclusion in this directory is not an endorsement.